デックスコムは Q2の利益を上回ったが,全年予測を下回った. DexCom beat Q2 earnings but fell short on full-year guidance, causing its stock to dip despite strong results.

デックスコム (DXCM) は,0.61ドルのEPSと12億1千万ドルの収益で,予測を上回る強力なQ22025の利益を発表したが,同社の2025年全年の収益予測が期待を下回った後,株式は下落した. DexCom (DXCM) reported strong Q2 2025 earnings with $0.61 EPS and $1.21 billion in revenue, surpassing estimates, but its stock dipped after the company’s full-year 2025 revenue forecast fell short of expectations. 2025年11月3日閲覧. ^ 株式は5.8.22で取引されたが,平成52週度の最高額の24.2%を下回るままであり,過去にリフトされた5.31ドルから6.113ドルまで重要な歴史的支援範囲に近づいた. The stock, trading at $58.22 on November 3, 2025, remains 24.2% below its 52-week high and is near a key historical support range of $55.31 to $61.13, where it has previously rebounded. 分析者は"適度な買い"の評価を維持し,目標値が91.65ドルである. Despite a 16.8% year-to-date decline, analysts maintain a "Moderate Buy" rating with a $91.65 target.